TrialHepatology (Baltimore, Md.)2016

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.

Paul Kwo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.